P/E at 34.37 vs Industry's 36.69: What the Data Shows for Sun Pharmaceutical Industries Ltd

Valuation Picture: Modest Discount Amid Sector Premiums

The current P/E of Sun Pharmaceutical Industries Ltd at 34.37 is below the industry average of 36.69, indicating a valuation discount of approximately 6.3%. This suggests that the market is pricing the stock slightly more conservatively than its sector peers, despite its large-cap status and established market presence. The sector itself commands a relatively high P/E, reflecting growth expectations and the defensive qualities often attributed to pharmaceutical companies. The discount could imply concerns over near-term earnings growth or competitive pressures, but it also offers a valuation buffer compared to the broader industry. Previously rated Buy, what is Sun Pharma’s current rating? This valuation context is critical for investors weighing the stock’s risk-reward profile.

Performance Across Timeframes: Divergent Momentum

Examining the stock’s returns reveals a divergence between short- and medium-term performance. Over the past year, Sun Pharmaceutical Industries Ltd has delivered a positive return of 9.88%, significantly outperforming the Sensex’s negative 10.91% return. This outperformance extends to longer horizons as well, with three-year and five-year returns of 60.33% and 118.87% respectively, both well ahead of the Sensex’s 10.24% and 21.10% gains. However, the recent three-month period tells a different story: the stock declined 5.73%, underperforming the Sensex’s 6.96% fall but still reflecting weakness. The one-month return of -5.45% closely mirrors the Sensex’s -5.44%, while the one-week and one-day performances show sharper underperformance, down 2.42% and 0.80% respectively versus the Sensex’s -0.58% and +0.61%. This pattern suggests that short-term selling pressure has intensified, possibly due to sector-specific or company-specific factors. Is this a temporary setback or a sign of deeper challenges?

Moving Average Configuration: Bearish Technical Setup

The technical picture for Sun Pharmaceutical Industries Ltd is notably weak. The stock is trading below all key moving averages: 5-day, 20-day, 50-day, 100-day, and 200-day. This comprehensive positioning below short-, medium-, and long-term averages indicates a sustained downtrend rather than a transient correction. The absence of any recent bounce above these averages suggests that the stock has yet to find technical support or trigger a recovery phase. Such a configuration often signals investor caution and may reflect underlying fundamental concerns or broader sector headwinds. The current three-day consecutive decline, resulting in a cumulative 4.55% fall, reinforces this bearish momentum. The 5% surge partially reverses a 6.45% monthly decline — is this a genuine recovery or a relief rally that will fade at the 50 DMA? The moving average configuration provides the clearest answer.

Sector Context: Mixed Results in Pharmaceuticals & Biotechnology

The Pharmaceuticals & Biotechnology sector, to which Sun Pharmaceutical Industries Ltd belongs, has exhibited a mixed performance landscape recently. While some companies have managed to post positive returns, others have struggled with flat or negative results amid regulatory pressures, pricing challenges, and competitive dynamics. The sector’s average P/E of 36.69 reflects investor expectations for growth and innovation, but also the premium placed on defensive qualities during volatile markets. Within this context, should investors in Sun Pharma hold, buy more, or reconsider? The sector’s varied performance underscores the importance of company-specific fundamentals and technicals in assessing investment merit.

Rating Context: Previously Rated Buy, Now Reassessed

Sun Pharmaceutical Industries Ltd was previously rated Buy by MarketsMOJO, with a Mojo Score of 67.0. The rating was updated on 03 Sep 2026, reflecting a reassessment of the company’s fundamentals, valuation, and technical indicators. While the current rating is not disclosed, the change signals a shift in the evaluation of the stock’s risk and reward profile. The combination of a modest valuation discount, divergent performance across timeframes, and a bearish moving average configuration likely influenced this reassessment. What is the current rating for Sun Pharma following this update? This question remains central for investors monitoring the stock’s trajectory.

Conclusion: A Complex Data-Driven Picture

The data for Sun Pharmaceutical Industries Ltd presents a multifaceted narrative. The stock trades at a slight valuation discount to its sector, which itself commands a premium P/E reflecting growth expectations. Its one-year and longer-term returns have outperformed the Sensex by a wide margin, yet recent months have seen a reversal in momentum with underperformance and a bearish technical setup below all major moving averages. The sector’s mixed results add further complexity to the assessment. Previously rated Buy, the stock’s rating was updated recently, signalling a reassessment of its outlook. Should investors in Sun Pharma hold, buy more, or reconsider? The current rating provides the answer.

Get 33% Off on our 1 Year Plan - Limited Period Only! Start Today